低磷酸酯酶症患者登记
低磷酸酯酶症 (HPP) 患者的观察性、纵向、前瞻性、长期登记
In this prospective, observational, long term registry patients of all ages with a diagnosis of hypophosphatasia (HPP) are followed at participating sites in multiple countries.
研究概览
地位
条件
详细说明
The HPP Registry is an observational, prospective, long-term registry designed to collect data on HPP epidemiology, disease history, clinical course, symptoms and burden of disease from patients of all ages who have a diagnosis of HPP.
Evaluation of safety and effectiveness data in patients with HPP who have/are receiving treatment with Asfotase alfa
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大
- Research Site
-
-
Ontario
-
Oakville、Ontario、加拿大
- Research Site
-
Ottawa、Ontario、加拿大
- Research Site
-
Toronto、Ontario、加拿大、M5G 2C4
- Research Site
-
-
-
-
-
Santander、哥伦比亚、681003
-
-
-
-
-
Chihuahua City、墨西哥
- Research Site
-
-
-
-
-
Linz、奥地利
- Research Site
-
-
-
-
-
Berlin、德国
- Research Site
-
Cologne、德国
- Research Site
-
Giessen、德国
- Research Site
-
Homburg、德国
- Research Site
-
Mainz、德国
- Research Site
-
-
Bavaria
-
Bad Reichenhall、Bavaria、德国
- Research Site
-
Würzburg、Bavaria、德国
- Research Site
-
-
North Rhine-Westphalia
-
Bochum、North Rhine-Westphalia、德国
- Research Site
-
Düsseldorf、North Rhine-Westphalia、德国
- Research Site
-
-
Saxony
-
Dresden、Saxony、德国
- Research Site
-
-
-
-
-
Florence、意大利
- Research Site
-
Pisa、意大利
- Research Site
-
Rome、意大利
- Research Site
-
San Giovanni Rotondo、意大利
- Research Site
-
-
Firenze
-
Sesto Fiorentino、Firenze、意大利
- Research Site
-
-
Milano
-
Milan、Milano、意大利、20132
- Research Site
-
-
-
-
-
Riyadh、沙特阿拉伯
- Research Site
-
-
-
-
-
Lyon、法国
- Research Site
-
Paris、法国
- Research Site
-
-
Haute Garonne
-
Toulouse、Haute Garonne、法国
- Research Site
-
-
Nord
-
Lille、Nord、法国
- Research Site
-
-
Paris
-
Paris、Paris、法国
- Research Site
-
-
Vienne
-
Poitiers、Vienne、法国
- Research Site
-
-
Île-de-France Region
-
Le Kremlin-Bicêtre、Île-de-France Region、法国
- Research Site
-
-
-
-
-
Lodz、波兰
- Research Site
-
Warsaw、波兰
- Research Site
-
-
-
-
-
Herston、澳大利亚
- Research Site
-
South Brisbane、澳大利亚
- Research Site
-
-
Victoria
-
Clayton、Victoria、澳大利亚
- Research Site
-
Parkville、Victoria、澳大利亚
- Research Site
-
-
-
-
Colorado
-
Centennial、Colorado、美国、80112
- Research Site
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- Research Site
-
-
Florida
-
Tampa、Florida、美国、33606
- Research Site
-
-
Georgia
-
Decatur、Georgia、美国、30033
- Research Site
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- Research Site
-
-
Massachusetts
-
Boston、Massachusetts、美国、02111
- Research Site
-
Boston、Massachusetts、美国、02115
- Research Site
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55454
- Research Site
-
-
Missouri
-
Kansas City、Missouri、美国、64108
- Research Site
-
St Louis、Missouri、美国、63110
- Research Site
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- Research Site
-
-
New York
-
Mineola、New York、美国、11501
- Research Site
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- Research Site
-
-
Ohio
-
Cincinnati、Ohio、美国、45229
- Research Site
-
Columbus、Ohio、美国、43205
- Research Site
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15224
- Research Site
-
-
Tennessee
-
Nashville、Tennessee、美国、37212
- Research Site
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- Research Site
-
-
Virginia
-
Charlottesville、Virginia、美国、22903
- Research Site
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- Research Site
-
-
-
-
-
Belfast、英国
- Research Site
-
-
Avon
-
Bristol、Avon、英国
- Research Site
-
-
Greater London
-
London、Greater London、英国
- Research Site
-
-
Leicestershire
-
Leicester、Leicestershire、英国、LE1 5WW
- Leicester Royal Infirmary
-
-
Middlesex
-
Stanmore、Middlesex、英国
- Research Site
-
-
Oxfordshire
-
Oxford、Oxfordshire、英国
- Research Site
-
-
South Yorkshire
-
Sheffield、South Yorkshire、英国
- Research Site
-
-
Tyne & Wear
-
Newcastle upon Tyne、Tyne & Wear、英国
- Research Site
-
-
West Midlands
-
Birmingham、West Midlands、英国
- Research Site
-
-
-
-
-
Madrid、西班牙
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with Hypophosphatasia (HPP)
描述
Inclusion Criteria:
- Male and female participants, of any age, with a confirmed diagnosis of HPP.
- Participant must have documented alkaline phosphatase (ALP) activity below the lower limit of normal for age and sex, or a documented ALPL gene mutation.
- Participant or legal representative is able to read and/or understand the informed consent and study questionnaires in the local language.
- Signed informed consent and medical records release by the patient or legal representative. Patient or patient's parent/legal representative must be willing and able to give written informed consent, and the patient must be willing to give written informed assent, if appropriate and required by local regulations.
Exclusion Criteria:
- Currently participating in an Alexion-sponsored clinical trial. Enrollment in the Registry will not exclude a patient from enrolling in a future clinical trial.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Natural History Information
大体时间:1 Year
|
To collect information on the natural history of HPP from patients of all ages, including pediatric patients and adults with HPP, regardless of age at onset. |
1 Year
|
|
Burden of Disease/Patient-reported Outcomes
大体时间:1 year
|
Age-appropriate PRO data will be collected using instruments to asses below: Pain, Motor Capacity, Functional Status/Disability, including Activities of Daily Living (ADL), Quality of Life (QoL) |
1 year
|
|
Characterize the epidemiology of the HPP population.
大体时间:1 year
|
To characterize the epidemiology of the HPP population. Inclusion of all classifications of HPP is planned: pediatric-onset (perinatal-, infantile-, and juvenile-onset), adult-onset, benign perinatal, and odontohypophosphatasia. |
1 year
|
|
Long-Term Safety and Effectiveness of Asfotase Alfa
大体时间:1 year
|
To collect and evaluate long-term safety and effectiveness data in HPP patients who have/are receiving treatment with asfotase alfa. |
1 year
|
合作者和调查者
出版物和有用的链接
一般刊物
- Dahir KM, Seefried L, Kishnani PS, Petryk A, Hogler W, Linglart A, Martos-Moreno GA, Ozono K, Fang S, Rockman-Greenberg C. Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry. Orphanet J Rare Dis. 2022 Jul 19;17(1):277. doi: 10.1186/s13023-022-02393-8.
- Dahir KM, Kishnani PS, Martos-Moreno GA, Linglart A, Petryk A, Rockman-Greenberg C, Martel SE, Ozono K, Hogler W, Seefried L. Impact of muscular symptoms and/or pain on disease characteristics, disability, and quality of life in adult patients with hypophosphatasia: A cross-sectional analysis from the Global HPP Registry. Front Endocrinol (Lausanne). 2023 Mar 27;14:1138599. doi: 10.3389/fendo.2023.1138599. eCollection 2023.
- Hogler W, Linglart A, Petryk A, Kishnani PS, Seefried L, Fang S, Rockman-Greenberg C, Ozono K, Dahir K, Martos-Moreno GA. Growth and disease burden in children with hypophosphatasia. Endocr Connect. 2023 Apr 25;12(5):e220240. doi: 10.1530/EC-22-0240. Print 2023 May 1.
- Hogler W, Langman C, Gomes da Silva H, Fang S, Linglart A, Ozono K, Petryk A, Rockman-Greenberg C, Seefried L, Kishnani PS. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord. 2019 Feb 14;20(1):80. doi: 10.1186/s12891-019-2420-8.
- Kishnani PS, Martos-Moreno GA, Linglart A, Petryk A, Messali A, Fang S, Rockman-Greenberg C, Ozono K, Hogler W, Seefried L, Dahir KM. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry. Orphanet J Rare Dis. 2024 Mar 8;19(1):109. doi: 10.1186/s13023-024-03048-6.
- Seefried L, Dahir K, Petryk A, Hogler W, Linglart A, Martos-Moreno GA, Ozono K, Fang S, Rockman-Greenberg C, Kishnani PS. Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry. J Bone Miner Res. 2020 Nov;35(11):2171-2178. doi: 10.1002/jbmr.4130. Epub 2020 Aug 10.
- Martos-Moreno GA, Rockman-Greenberg C, Ozono K, Petryk A, Kishnani PS, Dahir KM, Seefried L, Fang S, Hogler W, Linglart A. Clinical Profiles of Children with Hypophosphatasia prior to Treatment with Enzyme Replacement Therapy: An Observational Analysis from the Global HPP Registry. Horm Res Paediatr. 2024;97(3):233-242. doi: 10.1159/000531865. Epub 2023 Jul 13.
- Kishnani PS, Seefried L, Dahir KM, Martos-Moreno GA, Linglart A, Petryk A, Mowrey WR, Fang S, Ozono K, Hogler W, Rockman-Greenberg C. New insights into the landscape of ALPL gene variants in patients with hypophosphatasia from the Global HPP Registry. Am J Med Genet A. 2024 Nov;194(11):e63781. doi: 10.1002/ajmg.a.63781. Epub 2024 Jun 17.
- Kishnani PS, Seefried L, Dahir KM, Martos-Moreno GA, Hogler W, Greenberg CR, Fang S, Petryk A, Mowrey WR, Linglart A, Ozono K. Disease burden by ALPL variant number in patients with non-life-threatening hypophosphatasia in the Global HPP Registry. J Med Genet. 2025 Mar 20;62(4):249-257. doi: 10.1136/jmg-2024-110383.
- Tornero C, Martos-Moreno GA, Guanabens N, Florez H, Ribera A, Aguado P. Clinical characterization and impact of hypophosphatasia in Spain: An observational analysis of the Spanish cohort included in the Global HPP Registry. Med Clin (Barc). 2025 Nov;165(5):107120. doi: 10.1016/j.medcli.2025.107120. Epub 2025 Jul 25. English, Spanish.
- Kishnani PS, Seefried L, Ozono K, Martos-Moreno GA, Rockman-Greenberg C, Fowler D, Burke LK, Mowrey WR, Rush ET, Ebeling PR, Hogler W, Linglart A, Fang S, Petryk A, Dahir KM. The Global Hypophosphatasia Registry: lessons learned from a decade of real-world data. Orphanet J Rare Dis. 2025 Nov 24;20(1):626. doi: 10.1186/s13023-025-04129-w.
- Kishnani PS, Ing S, Hoover-Fong J, Pallais JC, Voskopoja A, Fang S, Mowrey WR, Rush E, Dahir K. Burden of disease in US patients with skeletal versus muscular or pain manifestations of hypophosphatasia: An analysis from the Global HPP Registry. Bone. 2026 Oct;211:117996. doi: 10.1016/j.bone.2026.117996. Epub 2026 Jun 28.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ALX-HPP-501
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.